82 research outputs found
Clinical follow-up of long nontapered sirolimus-eluting coronary stent in real-world patients with de novo lesions. The Billar registry
Introduction and objectives: Coronary lesions with stent overlapping are associated with higher neointimal proliferation that leads to more restenosis. Furthermore, the tapering of coronary arteries is a major challenge when treating long coronary lesions. This study attempted to assess the safety and clinical level of performance of long nontapered sirolimus-eluting coronary stent systems (> 36 mm) to treat long and diffused de novo coronary lesions in real-world scenarios. Methods: This was a prospective, non-randomized, multicentre study that included 696 consecutive patients treated with the long nontapered BioMime sirolimus-eluting coronary stent system in long and diffused de novo coronary lesions. The safety endpoint was major adverse cardiovascular events defined as a composite of cardiac death, myocardial infarction, clinically driven target lesion revascularization, stent thrombosis, and major bleeding at the 12-month follow-up. Results: Of a total of 696 patients, 38.79% were diabetic. The mean age of all the patients was 64.6 +/- 14 years, and 80% were males. The indication for revascularization was acute coronary syndrome in 63.1%. A total of 899 lesions were identified out of which 742 were successfully treated with long BioMime stents (37 mm, 40 mm, 44 mm, and 48 mm). The cumulative incidence of major adverse cardiovascular events was 8.1% at the 12-month follow-up including cardiac death (2.09%), myocardial infarction (1.34%), and total stent thrombosis (0.5%). Conclusions: This study confirms the safety and good performance of long nontapered BioMime coronary stents to treat de novo coronary stenosis. Therefore, it can be considered a safe and effective treatment for long and diffused de novo coronary lesions in the routine clinical practice
Desarrollo de indicaciones de uso apropiado del implante transcateter de protesis valvular aortica en el tratamiento de la estenosis aortica grave sintomatica
En cubierta aparecen logos del Ministerio de Sanidad, Servicios Sociales e Igualdad y de la Red Espanola de Agencias de Evaluacion de Tecnologias y Prestaciones del SN
New generation DES in treatment of patients with multivessel coronary artery disease. Comparison of one year clinical outcomes of biolimus-eluting (Nobori) and everolimus-eluting (Xience/Promus) stents in COMPARE II study
Thrombosis in real practice with second generation DES in special settings: Myocardial infarction and left main coronary artery - Results from the ESTROFA-2 Spanish registry
Inmediate and mid term results of the E-Tryton Spanish registry for the treatment of bifurcations lesions
Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent: 3 year follow-up from the compare ii trial
Post-procedural and follow-up management in patients undergoing transcatheter aortic valve implantation: Results from the written (WoRldwIde TAVI ExpieNce) survey
Approach and procedural management in patients undergoing transcatheter aortic valve implantation: Results from the written (worldwide TAVI experience) survey
- …